Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure

doi:10.12998/wjcc.v12.i1.68

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2295)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

117

WORD

HTML

1227

Tables (1-6)

238

Sum=1599

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

110

Download

490

Sum=600

Jan 6, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68

Table 2 Response rates in the two groups

Group	Number of patients	Significant	Effective	Ineffective	Total efficacy rate
Observation group	33	22 (66.66)	9 (27.27)	2 (6.06)	31 (93.93)
Control group	32	7 (21.87)	15 (46.87)	10 (31.25)	22 (68.75)
χ²	-	-	-	-	6.847
P value	-	-	-	-	0.008

Data are presented as n (%).

Citation: Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
URL: https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.68